SAN FRANCISCO (EGMN) - A new 86-gene signature may add to metabolic imaging in guiding early treatment decisions for esophagogastric junction cancer, researchers reported.The leptin gene, among others, stood out as having the potential to become a clinically useful biomarker in analyses that were presented at a meeting on gastrointestinal cancers sponsored by the American Society of Clinical Oncology.Dr. Russell Petty of the University of Aberdeen (Scotland) and colleagues studied 182 patients with...